Aperio Group’s Clovis Oncology CLVS Stock Holding History
Bought
Maintained
Sold
Other funds holding CLVS
Aperio Group's CLVS Position: Q4 2020 in Review
Aperio Group reduced its Clovis Oncology (CLVS) stake by 63% in Q4 2020, selling an estimated $162K and leaving 18,924 shares worth $91K. The position accounts for ﹤0.01% of the portfolio, ranked #2384.
Aperio Group first reported a position in CLVS in Q1 2015 and has held it in 13 quarters since. The position peaked at $477K in Q2 2017. 159 funds tracked by Wall St. Rank hold CLVS as of Q4 2020.
- Aperio Group held 18,924 shares of Clovis Oncology worth $91K as of Q4 2020.
- Aperio Group sold 32,087 Clovis Oncology shares in Q4 2020, an estimated $162K.
- Clovis Oncology made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2384 holding.
- Aperio Group first reported a position in Clovis Oncology in Q1 2015 and has held it in 13 quarters since.
- Aperio Group's Clovis Oncology position peaked at $477K in Q2 2017.
- 159 funds tracked by Wall St. Rank held Clovis Oncology as of Q4 2020.
Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.